Regulation and modulation of antitumor immunity in pancreatic cancer

[1]  R. Dahlstrom,et al.  Challenges and opportunities , 2021, Foundations of a Sustainable Economy.

[2]  Noam Shental,et al.  The human tumor microbiome is composed of tumor type–specific intracellular bacteria , 2020, Science.

[3]  Kwok-Kin Wong,et al.  PD-L1 engagement on T cells promotes self-tolerance and suppression of neighboring macrophages and effector T cells in cancer , 2020, Nature Immunology.

[4]  K. Murphy,et al.  Dendritic Cell Paucity Leads to Dysfunctional Immune Surveillance in Pancreatic Cancer. , 2020, Cancer cell.

[5]  R. DePinho,et al.  Oncogenic Kras driven metabolic reprogramming in pancreas cancer cells utilizes cytokines from the tumor microenvironment. , 2020, Cancer discovery.

[6]  G. Gupta,et al.  B cell–Derived IL35 Drives STAT3-Dependent CD8+ T-cell Exclusion in Pancreatic Cancer , 2020, Cancer Immunology Research.

[7]  A. Maitra,et al.  Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer , 2020, Journal for ImmunoTherapy of Cancer.

[8]  D. Bar-Sagi,et al.  Tumor Cell-Derived IL-1β Promotes Desmoplasia and Immune Suppression in Pancreatic Cancer. , 2020, Cancer research.

[9]  Michelle A. Anderson,et al.  Regulatory T cell depletion alters the tumor microenvironment and accelerates pancreatic carcinogenesis. , 2020, Cancer discovery.

[10]  S. Leach,et al.  ILC2s amplify PD-1 blockade by activating tissue-specific cancer immunity , 2020, Nature.

[11]  L. Diaz,et al.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Desai,et al.  The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity , 2019, Nature.

[13]  Myung Ah Lee,et al.  Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma: A Phase 2 Randomized Clinical Trial. , 2019, JAMA oncology.

[14]  S. Pushalkar,et al.  The Fungal Mycobiome Promotes Pancreatic Oncogenesis via MBL Activation , 2019, Nature.

[15]  J. Tobias,et al.  Tumor cell-intrinsic EPHA2 suppresses anti-tumor immunity by regulating PTGS2 (COX-2). , 2019, The Journal of clinical investigation.

[16]  A. Osipov,et al.  Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape , 2019, Journal of Immunotherapy for Cancer.

[17]  A. Eresen,et al.  Natural killer cell-based adoptive transfer immunotherapy for pancreatic ductal adenocarcinoma in a KrasLSL-G12D p53LSL-R172H Pdx1-Cre mouse model. , 2019, American journal of cancer research.

[18]  Christine B. Peterson,et al.  Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes , 2019, Cell.

[19]  Xianjun Yu,et al.  Nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic cancer: a systematic review and meta-analysis , 2019, Journal of Cancer.

[20]  L. Rohlin,et al.  Efficient Tumor Clearance and Diversified Immunity through Neoepitope Vaccines and Combinatorial Immunotherapy , 2019, Cancer Immunology Research.

[21]  R. Fields,et al.  Agonism of CD11b reprograms innate immunity to sensitize pancreatic cancer to immunotherapies , 2019, Science Translational Medicine.

[22]  R. Sears,et al.  Innate αβ T cells Mediate Antitumor Immunity by Orchestrating Immunogenic Macrophage Programming. , 2019, Cancer discovery.

[23]  B. Wilky.  Immune checkpoint inhibitors: The linchpins of modern immunotherapy , 2019, Immunological reviews.

[24]  Song-Cheol Kim,et al.  Progressive Impairment of NK Cell Cytotoxic Degranulation Is Associated With TGF-β1 Deregulation and Disease Progression in Pancreatic Cancer , 2019, Front. Immunol..

[25]  V. Balachandran,et al.  Broadening the Impact of Immunotherapy to Pancreatic Cancer: Challenges and Opportunities. , 2019, Gastroenterology.

[26]  Jin‐Young Jang,et al.  Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients , 2019, Front. Immunol..

[27]  M. Vignali,et al.  Mobilization of CD8+ T Cells via CXCR4 Blockade Facilitates PD-1 Checkpoint Therapy in Human Pancreatic Cancer , 2019, Clinical Cancer Research.

[28]  P. Loke,et al.  Specialized dendritic cells induce tumor-promoting IL-10+IL-17+ FoxP3neg regulatory CD4+ T cells in pancreatic carcinoma , 2019, Nature Communications.

[29]  F. Balkwill,et al.  Discrepancies in the Tumor Microenvironment of Spontaneous and Orthotopic Murine Models of Pancreatic Cancer Uncover a New Immunostimulatory Phenotype for B Cells , 2019, Front. Immunol..

[30]  N. Ibrahim,et al.  Pembrolizumab treatment of advanced neuroendocrine tumors: Results from the phase II KEYNOTE-158 study. , 2019, Journal of Clinical Oncology.

[31]  J. Yap,et al.  Protective autophagy elicited by RAF→MEK→ERK inhibition suggests a treatment strategy for RAS-driven cancers , 2019, Nature Medicine.

[32]  C. Iacobuzio-Donahue,et al.  Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer , 2019, Proceedings of the National Academy of Sciences.

[33]  D. Bar-Sagi,et al.  BTK SIGNALING DRIVES CD1dhiCD5+ REGULATORY B CELL DIFFERENTIATION TO PROMOTE PANCREATIC CARCINOGENESIS , 2018, Oncogene.

[34]  A. Rademaker,et al.  Ipilimumab and Gemcitabine for Advanced Pancreatic Cancer: A Phase Ib Study. , 2016, The oncologist.

[35]  H. Kocher,et al.  Pancreatic Cancer , 2019, Methods in Molecular Biology.

[36]  K. Kong,et al.  An Antibody Designed to Improve Adoptive NK-Cell Therapy Inhibits Pancreatic Cancer Progression in a Murine Model , 2018, Cancer Immunology Research.

[37]  Jingcheng Yang,et al.  Analysis of PD-1 related immune transcriptional profile in different cancer types , 2018, Cancer Cell International.

[38]  H. Eguchi,et al.  Possible involvement of Enterococcus infection in the pathogenesis of chronic pancreatitis and cancer. , 2018, Biochemical and biophysical research communications.

[39]  S. Shin,et al.  KRAS targeting antibody synergizes anti-cancer activity of gemcitabine against pancreatic cancer. , 2018, Cancer letters.

[40]  E. Jaffee,et al.  Targeting myeloid-inflamed tumor with anti-CSF-1R antibody expands CD137+ effector T-cells in the murine model of pancreatic cancer , 2018, Journal of Immunotherapy for Cancer.

[41]  P. A. Harris,et al.  RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer. , 2018, Cancer cell.

[42]  Manish R. Patel,et al.  PEGylated IL-10 (Pegilodecakin) Induces Systemic Immune Activation, CD8+ T Cell Invigoration and Polyclonal T Cell Expansion in Cancer Patients. , 2018, Cancer cell.

[43]  M. Maeurer,et al.  KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic Cancer , 2018, Front. Oncol..

[44]  S. Lowe,et al.  Tumor Cell‐Intrinsic Factors Underlie Heterogeneity of Immune Cell Infiltration and Response to Immunotherapy , 2018, Immunity.

[45]  Sabita Roy,et al.  Gut Microbiota Promotes Tumor Growth in Mice by Modulating Immune Response. , 2018, Gastroenterology.

[46]  D. Torigian,et al.  Activity of Mesothelin-Specific Chimeric Antigen Receptor T Cells Against Pancreatic Carcinoma Metastases in a Phase 1 Trial. , 2018, Gastroenterology.

[47]  R. Andersson,et al.  Targeting dendritic cells in pancreatic ductal adenocarcinoma , 2018, Cancer Cell International.

[48]  A. Fodor,et al.  Intestinal microbiota enhances pancreatic carcinogenesis in preclinical models , 2018, Carcinogenesis.

[49]  A. Biankin,et al.  CSF1R+ Macrophages Sustain Pancreatic Tumor Growth through T Cell Suppression and Maintenance of Key Gene Programs that Define the Squamous Subtype , 2018, Cell reports.

[50]  S. Pushalkar,et al.  The Pancreatic Cancer Microbiome Promotes Oncogenesis by Induction of Innate and Adaptive Immune Suppression. , 2018, Cancer discovery.

[51]  R. Aft,et al.  Breast and pancreatic cancer interrupt IRF8-dependent dendritic cell development to overcome immune surveillance , 2018, Nature Communications.

[52]  R. Qin,et al.  Regulatory B cells induced by pancreatic cancer cell-derived interleukin-18 promote immune tolerance via the PD-1/PD-L1 pathway , 2017, Oncotarget.

[53]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[54]  S. Carr,et al.  Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells. , 2018, Cancer research.

[55]  Donna Neuberg,et al.  Analysis of Fusobacterium persistence and antibiotic response in colorectal cancer , 2017, Science.

[56]  W. Gillanders,et al.  Targeting both tumour-associated CXCR2+ neutrophils and CCR2+ macrophages disrupts myeloid recruitment and improves chemotherapeutic responses in pancreatic ductal adenocarcinoma , 2017, Gut.

[57]  Mithat Gönen,et al.  Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer , 2017, Nature.

[58]  Noam Shental,et al.  Potential role of intratumor bacteria in mediating tumor resistance to the chemotherapeutic drug gemcitabine , 2017, Science.

[59]  Kecheng Xu,et al.  Percutaneous irreversible electroporation combined with allogeneic natural killer cell immunotherapy for patients with unresectable (stage III/IV) pancreatic cancer: a promising treatment , 2017, Journal of Cancer Research and Clinical Oncology.

[60]  Tao Shen,et al.  Prognostic value of programmed cell death protein 1 expression on CD8+ T lymphocytes in pancreatic cancer , 2017, Scientific Reports.

[61]  D. Bar-Sagi,et al.  Crosstalk between Regulatory T Cells and Tumor-Associated Dendritic Cells Negates Anti-tumor Immunity in Pancreatic Cancer , 2017, Cell reports.

[62]  G. Weiss,et al.  A phase Ib study of pembrolizumab plus chemotherapy in patients with advanced cancer (PembroPlus) , 2017, British Journal of Cancer.

[63]  G. Miller,et al.  NLRP3 signaling drives macrophage-induced adaptive immune suppression in pancreatic carcinoma , 2017, The Journal of experimental medicine.

[64]  R. Jesenofsky,et al.  Interleukin-15 stimulates natural killer cell-mediated killing of both human pancreatic cancer and stellate cells , 2017, Oncotarget.

[65]  G. Miller,et al.  Cancer Manipulation of Host Physiology: Lessons from Pancreatic Cancer. , 2017, Trends in molecular medicine.

[66]  Souptik Barua,et al.  Spatial computation of intratumoral T cells correlates with survival of patients with pancreatic cancer , 2017, Nature Communications.

[67]  B. Ueberheide,et al.  Dectin-1 Activation on Macrophages by Galectin-9 Promotes Pancreatic Carcinoma and Peritumoral Immune-Tolerance , 2017, Nature Medicine.

[68]  Lin Zhou,et al.  Cancer‐associated fibroblasts promote M2 polarization of macrophages in pancreatic ductal adenocarcinoma , 2017, Cancer medicine.

[69]  N. Bhattacharya,et al.  An Immunosuppressive Dendritic Cell Subset Accumulates at Secondary Sites and Promotes Metastasis in Pancreatic Cancer. , 2017, Cancer research.

[70]  E. Furth,et al.  CXCR2-Dependent Accumulation of Tumor-Associated Neutrophils Regulates T-cell Immunity in Pancreatic Ductal Adenocarcinoma , 2016, Cancer Immunology Research.

[71]  Y. Miao,et al.  Altered expression of CD226 and CD96 on natural killer cells in patients with pancreatic cancer , 2016, Oncotarget.

[72]  D. Bar-Sagi,et al.  γδ T Cells Support Pancreatic Oncogenesis by Restraining αβ T Cell Activation , 2016, Cell.

[73]  Camille Guillerey,et al.  Targeting natural killer cells in cancer immunotherapy , 2016, Nature Immunology.

[74]  M. Manns,et al.  Administration of Gemcitabine After Pancreatic Tumor Resection in Mice Induces an Antitumor Immune Response Mediated by Natural Killer Cells. , 2016, Gastroenterology.

[75]  A. V. Nguyen,et al.  Macrophage PI3Kγ Drives Pancreatic Ductal Adenocarcinoma Progression. , 2016, Cancer discovery.

[76]  L. Wood,et al.  Pancreatic cancer , 2016, The Lancet.

[77]  M. Pasca di Magliano,et al.  Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer , 2016, Gut.

[78]  A. Biankin,et al.  CXCR2 Inhibition Profoundly Suppresses Metastases and Augments Immunotherapy in Pancreatic Ductal Adenocarcinoma , 2016, Cancer cell.

[79]  Sarah I. Alothman,et al.  Radiation Therapy Induces Macrophages to Suppress T-Cell Responses Against Pancreatic Tumors in Mice. , 2016, Gastroenterology.

[80]  D. Weaver,et al.  Targeting Focal Adhesion Kinase Renders Pancreatic Cancers Responsive to Checkpoint Immunotherapy , 2016, Nature Medicine.

[81]  Kathryn J Fowler,et al.  Targeting tumour-associated macrophages with CCR2 inhibition in combination with FOLFIRINOX in patients with borderline resectable and locally advanced pancreatic cancer: a single-centre, open-label, dose-finding, non-randomised, phase 1b trial. , 2016, The Lancet. Oncology.

[82]  G. Beatty,et al.  IFNγ and CCL2 Cooperate to Redirect Tumor-Infiltrating Monocytes to Degrade Fibrosis and Enhance Chemotherapy Efficacy in Pancreatic Carcinoma. , 2016, Cancer discovery.

[83]  Crispin J. Miller,et al.  Oncogenic KRAS Regulates Tumor Cell Signaling via Stromal Reciprocation , 2016, Cell.

[84]  D. Allman,et al.  Hif1a Deletion Reveals Pro-Neoplastic Function of B Cells in Pancreatic Neoplasia. , 2016, Cancer discovery.

[85]  D. Bar-Sagi,et al.  IL35-Producing B Cells Promote the Development of Pancreatic Neoplasia. , 2016, Cancer discovery.

[86]  A. V. Nguyen,et al.  Bruton Tyrosine Kinase-Dependent Immune Cell Cross-talk Drives Pancreas Cancer. , 2016, Cancer discovery.

[87]  Sarah I. Alothman,et al.  The Necrosome Promotes Pancreas Oncogenesis via CXCL1 and Mincle Induced Immune Suppression , 2016, Nature.

[88]  Hai Hu,et al.  The M2 phenotype of tumor-associated macrophages in the stroma confers a poor prognosis in pancreatic cancer , 2016, Tumor Biology.

[89]  T. Sayers,et al.  NK Cells Preferentially Target Tumor Cells with a Cancer Stem Cell Phenotype , 2015, The Journal of Immunology.

[90]  C. Clendenin,et al.  Exclusion of T Cells From Pancreatic Carcinomas in Mice Is Regulated by Ly6C(low) F4/80(+) Extratumoral Macrophages. , 2015, Gastroenterology.

[91]  Y. Kanai,et al.  Intratumoral tertiary lymphoid organ is a favourable prognosticator in patients with pancreatic cancer , 2015, British Journal of Cancer.

[92]  Edgar G. Engleman,et al.  Allogeneic IgG combined with dendritic cell stimuli induces anti-tumor T cell immunity , 2015, Nature.

[93]  D. Linehan,et al.  CSF1/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models. , 2015, Cancer research.

[94]  P. Darcy,et al.  Trafficking of T cells into tumors. , 2014, Cancer research.

[95]  Y. Miao,et al.  Elevation of MMP-9 and IDO induced by pancreatic cancer cells mediates natural killer cell dysfunction , 2014, BMC Cancer.

[96]  M. Sawyer,et al.  A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. , 2014 .

[97]  A. Maitra,et al.  A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. , 2014, Gastroenterology.

[98]  Benjamin D. Smith,et al.  Projecting cancer incidence and deaths to 2030: the unexpected burden of thyroid, liver, and pancreas cancers in the United States. , 2014, Cancer research.

[99]  A. Maitra,et al.  Oncogenic Kras activates a hematopoietic-to-epithelial IL-17 signaling axis in preinvasive pancreatic neoplasia. , 2014, Cancer cell.

[100]  P. Greenberg,et al.  Targeted depletion of an MDSC subset unmasks pancreatic ductal adenocarcinoma to adaptive immunity , 2014, Gut.

[101]  Derek S. Chan,et al.  Targeting CXCL12 from FAP-expressing carcinoma-associated fibroblasts synergizes with anti–PD-L1 immunotherapy in pancreatic cancer , 2013, Proceedings of the National Academy of Sciences.

[102]  Y. Miao,et al.  Comprehensive analysis of the percentage of surface receptors and cytotoxic granules positive natural killer cells in patients with pancreatic cancer, gastric cancer, and colorectal cancer , 2013, Journal of Translational Medicine.

[103]  L. Diaz,et al.  Evaluation of Ipilimumab in Combination With Allogeneic Pancreatic Tumor Cells Transfected With a GM-CSF Gene in Previously Treated Pancreatic Cancer , 2013, Journal of immunotherapy.

[104]  Z. Husain,et al.  Tumor-Derived Lactate Modifies Antitumor Immune Response: Effect on Myeloid-Derived Suppressor Cells and NK Cells , 2013, The Journal of Immunology.

[105]  Jonathan B. Mitchem,et al.  Inflammatory Monocyte Mobilization Decreases Patient Survival in Pancreatic Cancer: A Role for Targeting the CCL2/CCR2 Axis , 2013, Clinical Cancer Research.

[106]  E. Jaffee,et al.  Role of immune cells and immune-based therapies in pancreatitis and pancreatic ductal adenocarcinoma. , 2013, Gastroenterology.

[107]  R. A. Evans,et al.  CD40 immunotherapy for pancreatic cancer , 2013, Cancer Immunology, Immunotherapy.

[108]  Jonathan B. Mitchem,et al.  Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. , 2013, Cancer research.

[109]  Atsuo Ochi,et al.  MyD88 inhibition amplifies dendritic cell capacity to promote pancreatic carcinogenesis via Th2 cells , 2012, The Journal of experimental medicine.

[110]  C. Drake,et al.  Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. , 2012, The New England journal of medicine.

[111]  D. Bar-Sagi,et al.  Oncogenic Kras-induced GM-CSF production promotes the development of pancreatic neoplasia. , 2012, Cancer cell.

[112]  N. Jhala,et al.  Tumor-derived granulocyte-macrophage colony-stimulating factor regulates myeloid inflammation and T cell immunity in pancreatic cancer. , 2012, Cancer cell.

[113]  Brian Bierie,et al.  Inhibiting Cxcr2 disrupts tumor-stromal interactions and improves survival in a mouse model of pancreatic ductal adenocarcinoma. , 2011, The Journal of clinical investigation.

[114]  J. Parsons,et al.  Inhibition of Focal Adhesion Kinase by PF-562,271 Inhibits the Growth and Metastasis of Pancreatic Cancer Concomitant with Altering the Tumor Microenvironment , 2011, Molecular Cancer Therapeutics.

[115]  R. Ni,et al.  The Presence of IGHG1 in Human Pancreatic Carcinomas Is Associated With Immune Evasion Mechanisms , 2011, Pancreas.

[116]  S. Natsugoe,et al.  Significance of M2-polarized tumor-associated macrophage in pancreatic cancer. , 2011, The Journal of surgical research.

[117]  Shizuo Akira,et al.  Stat3/Socs3 activation by IL-6 transsignaling promotes progression of pancreatic intraepithelial neoplasia and development of pancreatic cancer. , 2011, Cancer cell.

[118]  Drew A. Torigian,et al.  CD40 Agonists Alter Tumor Stroma and Show Efficacy Against Pancreatic Carcinoma in Mice and Humans , 2011, Science.

[119]  M. Braga,et al.  Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer , 2011, The Journal of experimental medicine.

[120]  D. Bar-Sagi,et al.  Oncogenic KRas suppresses inflammation-associated senescence of pancreatic ductal cells. , 2010, Cancer cell.

[121]  Jonathan B. Mitchem,et al.  Induction of Th17 Cells in the Tumor Microenvironment Improves Survival in a Murine Model of Pancreatic Cancer , 2010, The Journal of Immunology.

[122]  S. Rosenberg,et al.  Phase 2 Trial of Single Agent Ipilimumab (Anti-CTLA-4) for Locally Advanced or Metastatic Pancreatic Adenocarcinoma , 2010, Journal of immunotherapy.

[123]  M. Korc,et al.  Acute pancreatitis markedly accelerates pancreatic cancer progression in mice expressing oncogenic Kras. , 2009, Biochemical and biophysical research communications.

[124]  D. Tuveson,et al.  Dynamics of the immune reaction to pancreatic cancer from inception to invasion. , 2007, Cancer research.

[125]  M. Barbacid,et al.  Chronic pancreatitis is essential for induction of pancreatic ductal adenocarcinoma by K-Ras oncogenes in adult mice. , 2007, Cancer cell.

[126]  S. Hirohashi,et al.  Prevalence of FOXP3+ Regulatory T Cells Increases During the Progression of Pancreatic Ductal Adenocarcinoma and Its Premalignant Lesions , 2006, Clinical Cancer Research.

[127]  G. Adler,et al.  Collagen type I induces disruption of E-cadherin-mediated cell-cell contacts and promotes proliferation of pancreatic carcinoma cells. , 2006, Cancer research.

[128]  E. Feuer,et al.  SEER Cancer Statistics Review, 1975-2003 , 2006 .

[129]  L. Coussens,et al.  Paradoxical roles of the immune system during cancer development , 2006, Nature Reviews Cancer.

[130]  T. Oshikiri,et al.  CD8+ Tumor-Infiltrating Lymphocytes Together with CD4+ Tumor-Infiltrating Lymphocytes and Dendritic Cells Improve the Prognosis of Patients with Pancreatic Adenocarcinoma , 2004, Pancreas.

[131]  E. Casper,et al.  Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas , 2004, Investigational New Drugs.

[132]  P. Allavena,et al.  The CC chemokine MCP-1/CCL2 in pancreatic cancer progression: regulation of expression and potential mechanisms of antimalignant activity. , 2003, Cancer research.

[133]  T. Eberlein,et al.  Prevalence of Regulatory T Cells Is Increased in Peripheral Blood and Tumor Microenvironment of Patients with Pancreas or Breast Adenocarcinoma1 , 2002, The Journal of Immunology.

[134]  A. Andrén-sandberg,et al.  Etiologic links between chronic pancreatitis and pancreatic cancer. , 1997, Scandinavian journal of gastroenterology.

[135]  A. Harris,et al.  Phase II study of gemcitabine in patients with advanced pancreatic cancer. , 1996, British Journal of Cancer.

[136]  H. Reber,et al.  Routes of spread of pathogens into the pancreas in a feline model of acute pancreatitis. , 1994, Gut.

[137]  PROMISING TREATMENT , 1977, Pediatrics.